Nonsteroidal anti-inflammatory drug

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
木曜日, 12月 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

A unique approach to cancer treatment: Piazza and his pharmacy team bring a new approach to cancer research at Auburn University

Retrieved on: 
金曜日, 12月 1, 2023
NSAID, Medicine, Apoptosis, Lung, Pancreatic cancer, Nonsteroidal anti-inflammatory drug, Research, Hope, Breast cancer, Colorectal cancer, Tissue, Breast Cancer Research Foundation, RAS, Headache, Patient, Multimedia, UAB, MCI, FDA, Arthritis, Collaboration, Familial adenomatous polyposis, Auburn University, Polyp, Sulindac, Biomedical Research, Drug discovery, University, Cancer, Financial toxicity, HCOP, Cell division, Harrison College, Breast, Bangladesh Technical Education Board, Cell, Southern Research, Pharmaceutical industry, Nursing, Mobile phone, Pharmacy, Auburn

Piazza joined the Harrison College of Pharmacy (HCOP) in 2021 as the W.W. Walker Professor and head of the Department of Drug Discovery and Development.

Key Points: 
  • Piazza joined the Harrison College of Pharmacy (HCOP) in 2021 as the W.W. Walker Professor and head of the Department of Drug Discovery and Development.
  • Along with his administrative responsibilities, Piazza continues his groundbreaking research as director of the newly created Cancer Research Center at HCOP.
  • Piazza is optimistic that their lead compound, ADT-1004, is an attractive drug candidate inching closer and closer to clinical trials.
  • Piazza is excited about what can be accomplished on The Plains to be a beacon of hope in the battle to fight cancer.

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

Retrieved on: 
火曜日, 11月 7, 2023
Patient, Rheumatology Research Foundation, Standard of care, Psoriasis, Headache, American College, VAS, Diarrhea, Research, Nausea, REM, MACR, Common, Amgen, University of Washington School of Medicine, Joint, University, AMGN, American College of Rheumatology, Nonsteroidal anti-inflammatory drug, Safety, LDA, Pain, ACR, BSA, Hospital, Body surface area, Disability, Psoriatic arthritis, Pharmaceutical industry, Medical imaging, Rheumatology

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.

Key Points: 
  • Placebo
    THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
  • FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years.
  • Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.
  • "These patients experienced a significant reduction in psoriatic disease activity, a crucial finding for those in the early stages of the condition."

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
水曜日, 11月 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
水曜日, 10月 25, 2023
Floater, Gland, Stomach, Glaucoma, Viral, Pressure, Health Canada, Dexamethasone, Disease, Risk, Ibuprofen, Allergy, Eye, Red, Nonsteroidal anti-inflammatory drug, Drug identification number, Tuberculosis, Fungal infection, Infection, Sale, Mouth, Burns, Throat, Health, Plasma protein binding, Aspirin, NPN, Rash, Iris cyst, Diabetes, Atrophoderma, Safety, Natural product, Patient, Nose, Prescription drug, Maharashtra University of Health Sciences, Asthma, Triamcinolone, DIN, Pregnancy, Retinal detachment, Pharmacy, Neostigmine, Xeroderma, Cataract, Tropical ulcer, Blurred vision, Herpes simplex, Itch, Skin, Absorption, Inflammation, Common, Hair, NSAID, Myasthenia gravis, Swelling, Weakness, Elasticity, Failure, Dietary supplement, Cosmetics

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

New to The Street Announces its Four Corporate Interviews Airing on Newsmax and The FOX Business Network

Retrieved on: 
金曜日, 9月 29, 2023
Internet, Fox Business, Theatrical company management, Privacy, Stone Brewing Co., Veterinarian, Management, Big Tech, DACVAA, Osteoarthritis, Interview, Horse, Innovation system, Organization, Liberty, Liberty Safe, Abbie Hoffman: American Rebel, Dog, United States Capitol, Host, Coffee, Growth, Hacking, Social media, CSE, FRA, Show, Water, Nonsteroidal anti-inflammatory drug, Worship Volume One: I Stand for You, FBI, Pour-over will, Veterinary medicine, DVM, Television presenter, American Made, Compound, PROMO, Champion, OTCQX, Multi, Cat, Cryptocurrency, Online shopping, Newsmax, Street

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- New to The Street , an FMW Media production, will air its four (4) corporate interviews on Newsmax and the FOX Business Network .

Key Points: 
  • NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- New to The Street , an FMW Media production, will air its four (4) corporate interviews on Newsmax and the FOX Business Network .
  • New to The Street airs on Newsmax on Saturday, September 30, 2023, at 3:30 PM ET, and the FOX Business Network on Monday, October 2, 2023, at 10:30 PM PT, featuring the following interviews:
    1).
  • Randy provides more information about the Company's recently announced relationship with Stone Brewing , a prominent US craft beer company.
  • The interview will air on the FOX Business Network on August 21, 2023, at 10:30 PM PT.

Annual Cycling Event in California Raises Over $1 Million to Fight Arthritis, Impacting Nearly 60 Million Adults and Hundreds of Thousands of Children in the U.S.

Retrieved on: 
水曜日, 9月 27, 2023
Volunteering, Amgen, Arthritis, Partnership, Education, Friends, Disability, Arthritis Foundation, Quality of life, Outside (magazine), Research, Kate, Science, CCC, Patient, Nonsteroidal anti-inflammatory drug, Autoimmune disease, Ibuprofen, Family, National Senior Classical League, Fatigue, Amusement park, Pharmaceutical industry, Tourism, California Coast Classic Bike Tour

Two hundred cyclists will embark on the eight-day, 525-mile tour while raising funds and awareness for the Arthritis Foundation and the nearly 60 million U.S. adults with arthritis.

Key Points: 
  • Two hundred cyclists will embark on the eight-day, 525-mile tour while raising funds and awareness for the Arthritis Foundation and the nearly 60 million U.S. adults with arthritis.
  • This year, at least 80 of the approximately 200 riders have identified themselves as living with arthritis.
  • It’s the number one cause of disability and a growing health crisis affecting nearly 60 million adults and hundreds of thousands of children in the U.S.
  • Since 1948, the Arthritis Foundation has invested over half a billion dollars in research, with more than $22 million coming directly from the California Coast Classic.

Premier Diversified Holdings Inc. Announces Letter of Intent for Acquisition of AJA Health and Wellness Ltd., Assured Diagnosis Inc., and AJA Therapeutics Inc.

Retrieved on: 
木曜日, 9月 21, 2023
Related party transaction, TSX Venture Exchange, The, AJA, ADI, Aspirin, Policy, News, Wellness, Minority, CT, Letter, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., GTA MyCar, Smartphone, Amalgamation, Apigenin, SEDAR, Diagnosis, THC, Medtech, Employment, Health, CAD, DHI, LOI, Nonsteroidal anti-inflammatory drug, Therapy, Flavonoid, ATI, MI, Funding, Bank statement, HBO, Cannabinoid, MRI, PDH, Chronic pain, Security (finance), Health insurance, Bank, Cryptocurrency, Audit, Exchange, Acquisition

VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Premier Diversified Holdings Inc. ("PDH" or the "Company") (TSXV: PDH) is pleased to announce it has entered into a non-binding letter of intent (the "LOI") among AJA Health and Wellness Ltd. ("AJA Health"), AJA Therapeutics Inc. ("ATI"), Assured Diagnosis Inc. ("ADI"), James Viccars, Elizabeth Bryant Viccars and Deluxe Holdings Inc. ("DHI"), dated September 20, 2023, 2023 (the "Letter of Intent"), pursuant to which, subject to regulatory approval including that of the TSX Venture Exchange (the "Exchange"), PDH intends to acquire (the “AJA Health Acquisition”) all of the issued and outstanding class A common shares (“AJA Class A Shares”) and series 2 preferred shares of AJA Health (“AJA Preferred Shares” and together with the AJA Class A Shares, the “AJA Shares”) and the issued and outstanding shares (the “ADI Shares”) of ADI (the “ADI Acquisition”) by way of share exchange, three-cornered amalgamation or other similar form of transaction, and to acquire all of the shares held by James Viccars, Elizabeth Bryant Viccars and DHI in the capital of ATI in exchange for shares of PDH (the “ATI Share Purchase” and together with the AJA Health Acquisition and the ADI Acquisition, the "Acquisition"). The final structure of the Acquisition is subject to receipt of tax, corporate and securities law advice.

Key Points: 
  • AJA Health and Wellness Ltd.
    AJA Health was incorporated on February 18, 2015 in Alberta under the name MyCare MedTech Inc.
  • AJA Health anticipates completing a private placement of up to 12,500,000 AJA Class A Shares prior to closing of the Acquisition.
  • PDH currently owns 6,015,382 AJA Preferred Shares and 5,144,000 AJA Class A Shares for a total of 11,159,382 AJA Shares and will have 11,278,180 AJA Shares upon the debt settlement with AJA Health which will occur prior to closing of the Acquisition.
  • AJA Health owns 25,000,000 ATI Shares and Each of Jim Viccars, Elizabeth Bryant Viccars and DHI own 500,000 ATI Shares.

What Ails You? Natural Pain-Relief Tips for 3 Common Aches

Retrieved on: 
火曜日, 9月 19, 2023
Headache, Ice, Compression, Elevation, Inflammation, Aspirin, Massage, Injury, Patient, Physician, Nonsteroidal anti-inflammatory drug, Pain management, Ibuprofen, Birth control, Poultry farming, Pain, Rest

In recognition of September being National Pain Awareness Month, at-home massager manufacturer Wahl partnered with board-certified anesthesiologist and pain specialist Dr. Anita Gupta to provide tips on how individuals can lead a more pain-free life.

Key Points: 
  • In recognition of September being National Pain Awareness Month, at-home massager manufacturer Wahl partnered with board-certified anesthesiologist and pain specialist Dr. Anita Gupta to provide tips on how individuals can lead a more pain-free life.
  • "There are easy, achievable solutions for those living with pain, including many non-medication options," explains Dr. Gupta.
  • For example, she offers the following natural pain-relief tips for three common ailments:
    Headaches: For those experiencing headaches, a simple yet effective remedy is resting your eyes and applying gentle pressure with a cool, wet washcloth.
  • The foregoing does not create a doctor-patient relationship and is not intended to replace any guidance from your own treating physicians.

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

Retrieved on: 
水曜日, 8月 30, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Nociception, Schnitzer, Spinal cord, Drug discovery, Clinical trial, Licensure, DSM-IV codes, United States patent law, Coronavirus Scientific Advisory Board, Medication, NMDA, Research, Brain, Tylenol, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Nonsteroidal anti-inflammatory drug, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Northwestern University, Food, Pharmaceutical industry, Dietary supplement, Vaccine, Poultry farming, Defense, Anesthesia, File, Chronic pain, Surgery

The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.

Key Points: 
  • The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.
  • In experimental models and clinical studies, NMDA antagonists have demonstrated attenuation of pain and shown potential to reduce opioid craving.